The Evaluation of the Role of (Pro)hepcidin in Anemia Encountered in Inflammatory Bowel Diseases

IF 0.3 Q3 MEDICINE, GENERAL & INTERNAL

Erciyes Medical Journal Pub Date : 2022-01-01 DOI:10.14744/etd.2022.95881

S. Acar

{"title":"The Evaluation of the Role of (Pro)hepcidin in Anemia Encountered in Inflammatory Bowel Diseases","authors":"S. Acar","doi":"10.14744/etd.2022.95881","DOIUrl":null,"url":null,"abstract":"Objective: Hepcidin is a peptide that acts as a hormone that provides iron homeostasis in the body and has antimicrobial activity. The synthesis of hepcidin is stimulated during inflammation and causes inflammation anemia. For this purpose, we aimed to determine the role of (pro)hepcidin in anemia in inflammatory bowel diseases (IBD) and its correlation with clinical and biochemical findings. Materials and Methods: A total of 61 patients, 19 (31.1%) of whom were diagnosed with Crohn’s disease (CD), 42 (68.9%) with ulcerative colitis (UC), and a control group of 23 were included. Hepcidin and biochemical parameters which are related to anemia were measured. Results: There was a significant difference between the CD group and vs control group in terms of hepcidin level. As the disease activity increases, the hepcidin level decreases with a probability of 83%. Hepcidin levels were found to be significantly lower in the CD group. Although hepcidin levels were lower in the UC group than in the control group, the result was not statistically significant. Conclusion: We didn’t detect a statistically significant difference in the level of hepcidin between IBD and the control group.","PeriodicalId":43995,"journal":{"name":"Erciyes Medical Journal","volume":"26 1","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Erciyes Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14744/etd.2022.95881","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 1

Abstract

Objective: Hepcidin is a peptide that acts as a hormone that provides iron homeostasis in the body and has antimicrobial activity. The synthesis of hepcidin is stimulated during inflammation and causes inflammation anemia. For this purpose, we aimed to determine the role of (pro)hepcidin in anemia in inflammatory bowel diseases (IBD) and its correlation with clinical and biochemical findings. Materials and Methods: A total of 61 patients, 19 (31.1%) of whom were diagnosed with Crohn’s disease (CD), 42 (68.9%) with ulcerative colitis (UC), and a control group of 23 were included. Hepcidin and biochemical parameters which are related to anemia were measured. Results: There was a significant difference between the CD group and vs control group in terms of hepcidin level. As the disease activity increases, the hepcidin level decreases with a probability of 83%. Hepcidin levels were found to be significantly lower in the CD group. Although hepcidin levels were lower in the UC group than in the control group, the result was not statistically significant. Conclusion: We didn’t detect a statistically significant difference in the level of hepcidin between IBD and the control group.

查看原文本刊更多论文

(Pro)hepcidin在炎症性肠病贫血中的作用评价

目的:Hepcidin是一种肽，作为一种激素，在体内提供铁稳态并具有抗菌活性。炎症刺激hepcidin的合成，引起炎症性贫血。为此，我们旨在确定(pro)hepcidin在炎症性肠病(IBD)贫血中的作用及其与临床和生化结果的相关性。材料与方法:共纳入61例患者，其中19例(31.1%)诊断为克罗恩病(CD)， 42例(68.9%)诊断为溃疡性结肠炎(UC)，对照组23例。测定与贫血相关的Hepcidin及生化指标。结果:CD组hepcidin水平与对照组比较差异有统计学意义。随着疾病活动度的增加，hepcidin水平以83%的概率下降。在乳糜泻组，Hepcidin水平明显降低。虽然UC组的hepcidin水平低于对照组，但结果无统计学意义。结论:IBD患者与对照组hepcidin水平无统计学差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Erciyes Medical Journal MEDICINE, GENERAL & INTERNAL-

自引率

0.00%

发文量

审稿时长

16 weeks

期刊介绍： Erciyes Medical Journal (Erciyes Med J) is the international, peer-reviewed, open access publication of Erciyes University School of Medicine. The journal, which has been in continuous publication since 1978, is a publication published on March, June, September, and December. The publication language of the journal is English. The journal accepts clinical and experimental research articles in different fields of medicine, original case reports, letters to the editor and invited reviews for publication. Research articles and case reports on regionally frequent and specific medical topics are prioritized. Manuscripts on national and international scientific meetings and symposiums and manuscripts sharing scientific correspondence and scientific knowledge between authors and their readers are also published.